DOPAMINE JUNO (Juno Pharmaceuticals Pty Ltd)
Product name
DOPAMINE JUNO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
136 (255 working days)
Active ingredients
dopamine hydrochloride
Registration type
New generic medicine
Indication
DOPAMINE JUNO (concentrated injection for infusion) is indicated for the correction of haemodynamic imbalance present in:
- Acute hypotension or shock associated with myocardial infarction, endotoxic septicaemia, trauma and renal failure.
- As an adjunct after open heart surgery, where there is persistent hypotension after correction of hypovolaemia.
- In chronic cardiac decompensation as in congestive failure.
Registration process
First generic
First approval of a medicine that contains the same active ingredient as and is bioequivalent to an existing medicine